Cited by 74Sphingolipid Metabolism and SignalingBone Metabolism and DiseasesBone health and treatments

Sphingosine 1-phosphate signaling in bone remodeling: multifaceted roles and therapeutic potential

Open access
Meshcheryakova, Anastasia, Mechtcheriakova, Diana, Pietschmann, Peter·2017·Expert Opinion on Therapeutic Targets

Abstract

INTRODUCTION: Sphingolipids belong to a complex class of lipid molecules that are crucially involved in the regulation of important biological processes including proliferation, migration and apoptosis. Given the significant progress made in understanding the sphingolipid pathobiology of several diseases, sphingolipid-related checkpoints emerge as attractive targets. Recent data indicate the multifaceted contribution of the sphingolipid machinery to osteoclast - osteoblast crosstalk, representing one of the pivotal interactions underlying bone homeostasis. Imbalances in the interplay of osteoblasts and osteoclasts might lead to bone-related diseases such as osteoporosis, rheumatoid arthritis, and bone metastases. Areas covered: We summarize and analyze the progress made in bone research in the context of the current knowledge of sphingolipid-related mechanisms regulating bone remodeling. Particular emphasis was given to bioactive sphingosine 1-phosphate (S1P) and S1P receptors (S1PRs). Moreover, the mechanisms of how dysregulations of this machinery cause bone diseases, are covered. Expert opinion: In the context of bone diseases, pharmacological interference with sphingolipid machinery may lead to novel directions in therapeutic strategies. Implementation of knowledge derived from in vivo animal models and in vitro studies using pharmacological agents to manipulate the S1P/S1PRs axes suggests S1PR2 and S1PR3 as potential drug targets, particularly in conjunction with technology for local drug delivery.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/14728222.2017.1332180

Cites

106 of 106 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Several osteoclast-derived factors released into the BRC have been identified and validated in genetically modified mouse models: CT-1, S1P, Wnt10B, BMP6, CTHRC1, C3a, and LIF.

    “Several osteoclast-derived factors released into the BRC have been identified and validated in genetically modified mouse models. These factors include cardiotrophin-1 (CT-1),228 S1P,229 Wnt10B, BMP6,230 collagen triple helix repeat-containing 1 (CTHRC1),231 complement factor 3a (C3a),232 and leukemia inhibitory factor (LIF).233”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Meshcheryakova, A., Mechtcheriakova, D., & Pietschmann, P.
Affiliations
Medical University of Vienna (AT)
Corresponding author
  • Mechtcheriakova, Diana
  • Pietschmann, Peter
Venue
Expert Opinion on Therapeutic Targets
Published
2017-06-07
Volume
21
Issue
7
Pages
725-737
ISSN
  • 1472-8222 (ISSN-L)
  • 1744-7631
OpenAlex
W2616346761
Cited by
74
References
106
Citations by year
2026: 5 · 2025: 3 · 2024: 7 · 2023: 6 · 2022: 10 · 2021: 11 · 2020: 13 · 2019: 11 · 2018: 5 · 2017: 3
FWCI
0.82
Type
journal article
Language
en
Open access
Locations
  • Expert Opinion on Therapeutic Targets (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
Austrian Science Fund (P23228-B19)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Sphingolipid Metabolism and Signaling
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
  • Health Sciences › Medicine › Oncology › Bone health and treatments
Keywords
sphingosine-1-phosphate, S1P receptors, bone remodeling, bone homeostasis, sphingolipids, osteoporosis, rheumatoid arthritis, bone metastasis, S1PR2, S1PR3, therapeutic target, local drug delivery
MeSH terms
Sphingosine-1-Phosphate Receptors, Animals, Bone and Bones, Bone Diseases, Humans, Lysophospholipids, Osteoblasts, Osteoclasts, Sphingolipids, Sphingosine, Drug Design, Signal Transduction, Drug Delivery Systems, Bone Remodeling, Receptors, Lysosphingolipid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review